Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the benefit of lidocaine perfusion in cancer related visceral pain resistant to morphinics. It is an efficacy study in adults and children and a randomized prospective study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
• Treatments: Lidocaine

Criteria

Inclusion Criteria:

• Patients suffering from cancer of any type, at any stage, hospitalized at the Institut Gustave Roussy

• Aged from 6 to 14 years old (group A) and from 15 to 70 years old (adults)

• Presenting visceral pain due to neurotoxic chemotherapy, due to the tumoral mass or to peritoneal carcinosis

• Pain resistant to morphinic treatment

Exclusion Criteria:

• Cardiac troubles, clinical cardiac insufficiency, or history of myocardial infarction (MI) of less than 3 months

• Neurological: non-controlled epilepsy, encephalopathy, or dementia

• Severe hepatic insufficiency

• Severe renal insufficiency

• Respiratory insufficiency

• Patients having surgery or in postoperative period

• Known deficit in G6PD, alanine exposure, or sulphamide treatment

• Porphyria

• Weight > 80 kg